FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

RAGUSA ROBERT P 		2. Issuer Name and Ticker or Trading Symbol

Twist Bioscience Corp [ TWST ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

C/O TWIST BIOSCIENCE CORPORATION, 455 MISSION BAY BOULEVARD SOUTH 		3. Date of Earliest Transaction (MM/DD/YYYY)

11/2/2018
(Street)

SAN FRANCISCO, CA 94158
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   11/2/2018     C    542203   A   (1) 542203   I   By Illumina, Inc.   (2)
Common Stock   11/2/2018     C    329305   A   (1) 871508   I   By Illumina, Inc.   (2)
Common Stock   11/2/2018     C    673378   A   (1) 1544886   I   By Illumina, Inc.   (2)
Common Stock   11/2/2018     C    157215   A   (1) 1702101   I   By Illumina, Inc.   (2)
Common Stock                  0   D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Series A Preferred Stock     (1) 11/2/2018     C         542203      (1)   (1) Common Stock   542203   $0.00   0   I   By Illumina, Inc.   (2)
Series B Preferred Stock     (1) 11/2/2018     C         329305      (1)   (1) Common Stock   329305   $0.00   0   I   By Illumina, Inc.   (2)
Series C Preferred Stock     (1) 11/2/2018     C         673378      (1)   (1) Common Stock   673378   $0.00   0   I   By Illumina, Inc.   (2)
Series D Preferred Stock     (1) 11/2/2018     C         157215      (1)   (1) Common Stock   157215   $0.00   0   I   By Illumina, Inc.   (2)

Explanation of Responses:
(1)  The Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock have no expiration date and converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering.
(2)  The Reporting Person is the Senior Vice President, Global Quality and Operations of Illumina, Inc. and has sole voting and dispositive power over the shares held of record by Illumina, Inc. The Reporting Person disclaims beneficial ownership in these shares except as to the Reporting Person's pecuniary interest therein.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
RAGUSA ROBERT P
C/O TWIST BIOSCIENCE CORPORATION
455 MISSION BAY BOULEVARD SOUTH
SAN FRANCISCO, CA 94158 		X



Signatures
/s/ William Solis, as Attorney-in-Fact 11/6/2018
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Twist Bioscience Charts.
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Twist Bioscience Charts.